TY - JOUR
T1 - PD-L1 Testing for Lung Cancer in 2019
T2 - Perspective From the IASLC Pathology Committee
AU - Lantuejoul, Sylvie
AU - Sound-Tsao, Ming
AU - Cooper, Wendy A.
AU - Girard, Nicolas
AU - Hirsch, Fred R.
AU - Roden, Anja C.
AU - Lopez-Rios, Fernando
AU - Jain, Deepali
AU - Chou, Teh Ying
AU - Motoi, Noriko
AU - Kerr, Keith M.
AU - Yatabe, Yasushi
AU - Brambilla, Elisabeth
AU - Longshore, John
AU - Papotti, Mauro
AU - Sholl, Lynette M.
AU - Thunnissen, Erik
AU - Rekhtman, Natasha
AU - Borczuk, Alain
AU - Bubendorf, Lukas
AU - Minami, Yuko
AU - Beasley, Mary Beth
AU - Botling, Johan
AU - Chen, Gang
AU - Chung, Jin Haeng
AU - Dacic, Sanja
AU - Hwang, David
AU - Lin, Dongmei
AU - Moreira, Andre
AU - Nicholson, Andrew G.
AU - Noguchi, Masayuki
AU - Pelosi, Giuseppe
AU - Poleri, Claudia
AU - Travis, William
AU - Yoshida, Akihiko
AU - Daigneault, Jillian B.
AU - Wistuba, Ignacio I.
AU - Mino-Kenudson, Mari
N1 - Publisher Copyright:
© 2019 International Association for the Study of Lung Cancer
PY - 2020/4
Y1 - 2020/4
N2 - The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic disease. Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. Multiple clinical trials for ICIs have evaluated a predictive value of PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells (ICs) by immunohistochemistry (IHC), for which different assays with specific IHC platforms were applied. Of those, some PD-L1 IHC assays have been validated for the prescription of the corresponding agent for first- or second-line treatment. However, not all laboratories are equipped with the dedicated platforms, and many laboratories have set up in-house or laboratory-developed tests that are more affordable than the generally expensive clinical trial–validated assays. Although PD-L1 IHC test is now deployed in most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging owing to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided. Because many articles have been published since the issue of the IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, this review by the IASLC Pathology Committee provides updates on the indications of ICIs for lung cancer in 2019 and discusses important considerations on preanalytical, analytical, and postanalytical aspects of PD-L1 IHC testing, including specimen type, validation of assays, external quality assurance, and training.
AB - The recent development of immune checkpoint inhibitors (ICIs) has led to promising advances in the treatment of patients with NSCLC and SCLC with advanced or metastatic disease. Most ICIs target programmed cell death protein 1 (PD-1) or programmed death ligand 1 (PD-L1) axis with the aim of restoring antitumor immunity. Multiple clinical trials for ICIs have evaluated a predictive value of PD-L1 protein expression in tumor cells and tumor-infiltrating immune cells (ICs) by immunohistochemistry (IHC), for which different assays with specific IHC platforms were applied. Of those, some PD-L1 IHC assays have been validated for the prescription of the corresponding agent for first- or second-line treatment. However, not all laboratories are equipped with the dedicated platforms, and many laboratories have set up in-house or laboratory-developed tests that are more affordable than the generally expensive clinical trial–validated assays. Although PD-L1 IHC test is now deployed in most pathology laboratories, its appropriate implementation and interpretation are critical as a predictive biomarker and can be challenging owing to the multiple antibody clones and platforms or assays available and given the typically small size of samples provided. Because many articles have been published since the issue of the IASLC Atlas of PD-L1 Immunohistochemistry Testing in Lung Cancer, this review by the IASLC Pathology Committee provides updates on the indications of ICIs for lung cancer in 2019 and discusses important considerations on preanalytical, analytical, and postanalytical aspects of PD-L1 IHC testing, including specimen type, validation of assays, external quality assurance, and training.
KW - Immunohistochemistry
KW - Immunotherapy
KW - NSCLC
KW - PD-L1
KW - SCLC
UR - http://www.scopus.com/inward/record.url?scp=85082097133&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85082097133&partnerID=8YFLogxK
U2 - 10.1016/j.jtho.2019.12.107
DO - 10.1016/j.jtho.2019.12.107
M3 - Review article
C2 - 31870882
AN - SCOPUS:85082097133
SN - 1556-0864
VL - 15
SP - 499
EP - 519
JO - Journal of Thoracic Oncology
JF - Journal of Thoracic Oncology
IS - 4
ER -